Imatinib Mesylate 100mg

Imatinib Mesylate 100mg – Quick Overview

Imatinib Mesylate 100mg is a prescription targeted cancer therapy (kinase inhibitor) used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and certain gastrointestinal stromal tumors (GIST). It works by blocking specific enzymes that drive cancer cell growth. Imatinib Mesylate 100mg must be prescribed and monitored by an oncologist, with regular lab testing throughout treatment.

Medical Supervision & Regulatory Status

Imatinib Mesylate 100mg is available only by prescription in the United States and is not sold over the counter. It was approved by the FDA in May 2001 for CML and later approved for unresectable and/or metastatic GIST expressing the c-kit receptor. Because it is a potent oncology medicine with serious potential toxicities, treatment requires close specialist supervision and ongoing laboratory monitoring.

Clinical Context

Chronic myeloid leukemia and GIST are cancers driven by specific abnormal enzyme (kinase) activity that causes uncontrolled cell growth. Without targeted treatment, these cancers can progress and significantly shorten survival.

Imatinib Mesylate 100mg represents one tablet strength used to build individualized daily doses, since total daily amounts are tailored to the specific cancer type, disease phase, and patient response.

Imatinib was one of the first targeted kinase inhibitors and remains a foundational treatment option; clinical trials have shown that imatinib produces clinical benefit in most patients with unresectable or metastatic GIST, extending median survival from 19 to 57 months.

How Imatinib Mesylate 100mg Works

Imatinib belongs to the kinase inhibitor drug class, a form of targeted cancer therapy. It works by targeting the BCR-ABL fusion protein in CML and c-KIT mutations in GIST, both of which are abnormal enzymes that drive uncontrolled growth of cancer cells.

By blocking these specific kinase enzymes, Imatinib Mesylate 100mg interferes with the cancer cell’s growth signal, helping to slow or stop disease progression in appropriately selected patients.

The prescribed dose should be administered orally, with a meal and a large glass of water, which supports consistent absorption and helps reduce gastrointestinal irritation.

What is Imatinib Mesylate 100mg?

• Drug Class: Kinase inhibitor (targeted oncology therapy)
• Active Ingredient: Imatinib mesylate (equivalent to 100mg imatinib)
• Mechanism: Inhibits BCR-ABL and c-KIT tyrosine kinases to block abnormal cancer cell growth signals
• Form: Oral film-coated tablet
• Dosing Frequency: Once daily or divided doses, depending on total prescribed dose
• Regulatory Status: Prescription-only (Rx) in the United States

Uses / Indications

• Chronic Myeloid Leukemia (Ph+ CML): Indicated for newly diagnosed adult and pediatric patients with Philadelphia chromosome positive CML in chronic phase, and for patients in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy.
• Gastrointestinal Stromal Tumors (GIST): Indicated for adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST, as well as unresectable or metastatic GIST.
• Other Rare Hematologic Conditions: May be used for certain other conditions involving specific genetic mutations, as determined by an oncologist.

How to Use / Dosage

All doses of Imatinib mesylate should be taken with a meal and a large glass of water. Doses of 400mg or 600mg are typically administered once daily, while an 800mg dose is given as 400mg twice a day. The number of 100mg tablets used depends on the total daily dose prescribed by the treating oncologist, which is individualized based on cancer type, disease stage, and response.

For patients unable to swallow tablets whole, they can be dissolved in water or apple juice. A dose should never be adjusted or skipped without physician guidance. If a dose is missed, contact the prescribing doctor for instructions rather than doubling the next dose. Imatinib Mesylate 100mg should not be stopped without medical guidance, as treatment interruption may allow disease progression.

Side Effects of Imatinib Mesylate 100mg

Most patients experience some side effects with Imatinib Mesylate 100mg, and close monitoring by an oncology team helps manage these safely.

Common side effects may include superficial edema, muscle cramps, musculoskeletal pain, rash, fatigue, headache, abdominal pain, and joint pain, along with nausea, vomiting, and diarrhea.

Serious side effects can include edema and severe fluid retention, severe hepatotoxicity including fatalities, gastrointestinal perforations, tumor lysis syndrome, and a decline in kidney function. Grade 3/4 events may include fluid retention such as pleural or pericardial effusions and ascites, skin rash, liver toxicity, and gastrointestinal hemorrhage.

Emergency Warning Signs — seek immediate medical attention if you experience:

• Sudden or severe abdominal pain (possible GI perforation or bleeding)
• Rapid, unexplained weight gain or severe swelling
• Yellowing of the skin or eyes, dark urine, or severe fatigue (possible liver injury)
• Shortness of breath or chest pain
• Signs of severe bleeding (black stools, coughing up blood, unusual bruising)
• Severe skin rash or blistering
• Signs of a severe allergic reaction (swelling, difficulty breathing)

Warnings & Precautions

Imatinib Mesylate 100mg carries important warnings for fluid retention and hepatotoxicity. Edema and severe fluid retention have occurred; patients should be weighed regularly, and unexpected rapid weight gain should be managed with drug interruption and diuretics as directed by a physician. Severe hepatotoxicity, including fatalities, may occur, so liver function should be assessed before starting treatment and monthly thereafter or as clinically indicated, especially when combined with other liver-affecting chemotherapy.

Regarding drug interactions, CYP3A4 inducers may decrease imatinib blood levels while CYP3A4 inhibitors may increase them; imatinib itself inhibits CYP3A4 and CYP2D6, which may raise levels of other drugs. Patients requiring anticoagulation should receive low-molecular-weight or standard heparin rather than warfarin. Imatinib mesylate can cause fetal harm when administered to a pregnant woman based on human and animal data, so effective contraception is advised during treatment and for a period after stopping; breastfeeding should be discussed with the oncology team.

Gastrointestinal perforations, some fatal, have been reported, and Grade 3/4 hemorrhage has been reported in patients with newly diagnosed CML and GIST, with GI tumor sites sometimes serving as the bleeding source. Growth retardation has been reported in children and pre-adolescents, so close monitoring of growth is recommended in pediatric patients.

Who Should Not Use This Medication

• Patients with a known allergy to imatinib or any tablet ingredient
• Patients with uncontrolled severe liver impairment, unless closely monitored by a specialist
• Pregnant patients, unless the treating oncologist determines the benefit outweighs the risk
• Patients without a valid prescription and active oncology supervision
• Patients unable to attend required lab monitoring visits

Storage Instructions

Store Imatinib Mesylate 100mg tablets at room temperature, protected from excess heat and moisture. Keep the container tightly closed and away from direct light. As with all oncology medications, store out of reach and sight of children and pets, and dispose of unused tablets through a medication take-back program rather than household trash.

Frequently Asked Questions

What is the cost of Imatinib Mesylate 100mg without insurance?

The cost without insurance depends on the seller, brand availability, and pack size, and may also vary by location and available discounts. Generic imatinib is generally far more affordable than brand-name Gleevec. Ask your pharmacist or oncology team about current pricing and assistance programs.

How can I order Imatinib Mesylate 100mg online?

A valid prescription from an oncologist is required to order Imatinib Mesylate 100mg. Typically, your prescription is sent directly by your doctor or uploaded to a licensed specialty pharmacy, which then arranges delivery. Always use verified, licensed pharmacies given the medication’s complexity and monitoring needs.

Is Imatinib Mesylate 100mg available over the counter?

No, Imatinib Mesylate 100mg is not available over the counter in most countries, including the United States. Regulations may vary by region, but this medication requires prescription and specialist oncology supervision due to its serious risk profile.

Does Imatinib Mesylate 100mg require a prescription?

Yes, Imatinib Mesylate 100mg requires a prescription in the United States and most countries. This ensures proper diagnosis, dose individualization, and ongoing monitoring for toxicity.

How long does Imatinib Mesylate 100mg take to work?

Response time varies by cancer type; some CML patients show improved blood counts within weeks, while deeper molecular responses can take several months of consistent treatment. Your oncologist will track response through regular blood and molecular testing.

Is it safe to stop taking Imatinib Mesylate 100mg suddenly?

No, stopping Imatinib Mesylate 100mg without medical guidance is not recommended, as it may allow the underlying cancer to progress. Any changes to treatment should only be made under close oncology supervision.

Can Imatinib Mesylate 100mg interact with other medications?

Yes, Imatinib Mesylate 100mg has significant interactions, particularly with CYP3A4 inhibitors/inducers and warfarin. Always share a complete list of your medications and supplements with your oncology team before starting or adjusting treatment.

References

• DailyMed (NIH) – Imatinib Mesylate Tablets Full Prescribing Information: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1debf3a0-7587-47d7-8ea6-e739698d7297
• MedlinePlus – Imatinib Drug Information: https://medlineplus.gov/druginfo/meds/a606018.html
• FDA – Gleevec (Imatinib Mesylate) Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf

Medical Disclaimer:

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified specialist or physician before using Imatinib Mesylate 100mg.